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Abstract
Prolactin is best known as the polypeptide anterior pituitary hormone, which regulates the development of the mammary gland.
However, it became clear over the last decade that prolactin contributes to a broad range of pathologies, including breast cancer.
Prolactin is also involved in angiogenesis via the release of pro-angiogenic factors by leukocytes and epithelial cells. However, whether
prolactin also influences endothelial cells, and whether there are functional consequences of prolactin-induced signalling in the perspec-
tive of angiogenesis, remains so far elusive. In the present study, we show that prolactin induces phosphorylation of ERK1/2 and STAT5
and induces tube formation of endothelial cells on Matrigel. These effects are blocked by a specific prolactin receptor antagonist, del1-
9-G129R-hPRL. Moreover, in an in vivo model of the chorioallantoic membrane of the chicken embryo, prolactin enhances vessel den-
sity and the tortuosity of the vasculature and pillar formation, which are hallmarks of intussusceptive angiogenesis. Interestingly, while
prolactin has only little effect on endothelial cell proliferation, it markedly stimulates endothelial cell migration. Again, migration was
reverted by del1-9-G129R-hPRL, indicating a direct effect of prolactin on its receptor. Immunohistochemistry and spectral imaging
revealed that the prolactin receptor is present in the microvasculature of human breast carcinoma tissue. Altogether, these results sug-
gest that prolactin may directly stimulate angiogenesis, which could be one of the mechanisms by which prolactin contributes to breast
cancer progression, thereby providing a potential tool for intervention.
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Introduction
Prolactin is best known as the polypeptide anterior pituitary hor-
mone, which regulates the development of the mammary gland
throughout female reproductive life. During pregnancy, prolactin
stimulates the expansion and differentiation of the lobuloalveolar
system. After delivery, prolactin induces the final induction of milk
protein gene expression and lactation [1]. Together with growth
hormone and placental lactogen, prolactin forms a family of hor-
mones that probably resulted from the duplication of one ances-
tral gene [2]. Besides this very well-known role in lactation, pro-
lactin is also produced in many other healthy as well as diseased
tissues, such as the mammary gland, prostate, skin, decidua,
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adipocytes and some immune cells, which all express the
 prolactin receptor [3]. Based on the almost ubiquitous distribution
of prolactin receptors, and an ever-growing list of extrapituitary
prolactin-expressing tissues, a wide array of functions beyond
 lactation has been documented or claimed for prolactin. In illustra-
tion, prolactin has been shown to regulate the immune responses
[2, 4, 5], indicated, for instance, by marked proliferation of the
pre-T lymphoma Nb2 cells in response to prolactin [6].
Recent evidence also suggests that prolactin may be involved
in cancer progression. Large epidemiological prospective studies,
conducted in patients with breast cancer, showed that high pro-
lactin levels prior to treatment are associated with treatment fail-
ure, earlier recurrence and worse overall survival [7]. In addition,
recent genetic data imply that polymorphisms in prolactin and the
prolactin receptor genes may contribute to the development of
breast adenomas and cancer [8–10]. These results are further
supported by in vivo studies. Prolactin has the ability to induce
tumour growth in an autocrine/paracrine fashion in murine mod-
els of prostate and breast cancer, which may help to understand
its role in human tumourigenesis [11]. In accordance with these
observations, prolactin stimulates the growth and motility of
human breast cancer cells in vitro [12]. The actions of prolactin
are mediated by at least six recognized prolactin receptor isoforms
(resulting from mRNA splicing variants) found on human breast
epithelium [12]. These different isoforms share an identical extra-
cellular and transmembrane domain [3]. Since the in vivo relevance
of the short prolactin receptor isoforms are unclear, the long pro-
lactin receptor isoform is considered the major isoform through
which prolactin transmits its signals, although the expression 
of the isoforms may differ between tissues and may depend on the
estrous cycle [2, 3, 13, 14]. The prolactin/prolactin-receptor com-
plex associates with and activates several signalling pathways,
such as STAT5 and ERK1/2, that are shared with other members
of the cytokine receptor superfamily [12]. Interestingly, over the
last decade, human prolactin analogues have been developed that
down-regulate the effects of either local prolactin (competitive
antagonism) or of the constitutively active receptor variants
(inverse agonism) [15]. Prolactin also plays an important role in
the dynamic process of angiogenesis. For instance, Erdmann and
co-workers elegantly showed that prolactin is involved in the
regression of angiogenesis during luteolysis [16], while genetic
ablation of the prolactin receptor induces angiogenesis defects in
the corpus luteum in mice, during the process of luteal transition
[17]. More studies support these findings. Indeed, when rat
 prolactin cDNA, fused to the cytomegalovirus promoter, was intro-
duced into mouse muscle by direct injection, evidence of marked
angiogenesis was found in the testis of these mice [18]. In a  
late-stage chicken chorioallantoic membrane (CAM) bioassay,
prolactin stimulated blood vessel formation [19]. In the above-
mentioned studies, the underlying cellular mechanisms of
 prolactin-induced angiogenesis have not been investigated.
Interestingly, prolactin can stimulate the expression of angiogenic
factors, such as vascular endothelial growth factor (VEGF), by the
epithelium, macrophages and leukocytes [20, 21]. Moreover, 
the prolactin receptor is expressed in the endothelium of the 
pulmonary artery, aorta, corpus luteum and umbilical vein from
bovine origin [22, 23]. Therefore, it was previously postulated that
the angiogenic effects of prolactin may be mediated through a
direct or an indirect effect (or both) on endothelial cells [24].
Against this background, we aimed to investigate the functional
consequences of prolactin receptor signalling in endothelial cells
with regard to angiogenesis, in the setting of breast cancer.
Materials and methods
Cells and culture
The murine endothelial cell line 2H11 was purchased from American Type
Culture Collection (ATCC; Manassas, VA, USA), and maintained in
Dulbecco’s minimal essential media (DMEM; Lonza, Basel, Switzerland)
supplemented with glutamate, 1% penicillin/streptomycin and 10% foetal
calf serum (FCS). This cell line has been shown to be useful in in vitro
angiogenesis assays for evaluating the potential angiogenic properties of
novel compounds [25, 26]. Human umbilical vein endothelial cells
(HUVEC) were isolated from fresh human umbilical cord veins and main-
tained in RPMI-1640 (Invitrogen, Carlsbad, CA, USA) supplemented with
10% human serum, 10% FCS, 1% glutamin (Invitrogen), 100 IU/ml peni-
cillin (Sigma-Aldrich, St. Louis, MO, USA) and 100 g/ml streptomycin
(Sigma-Aldrich) as previously described [27].
Human recombinant prolactin and the pure prolactin receptor antago-
nist del1-9-G129R-hPRL were prepared in the French laboratory as previ-
ously described [28]. Both human prolactin and del1-9-G129R are ligands
of the human and mouse prolactin receptor [28, 29]. The antagonist was
demonstrated to block activity of the long isoforms of mouse and human
prolactin receptors, using several in vitro bioassays [28]. It also acts as a
pure antagonist in vivo, as was assessed by competitive inhibition of pro-
lactin-triggered signalling cascades in various mouse target tissues known
to express the prolactin receptor endogenously, such as liver, mammary
gland and prostate [28, 29]. As the extracellular ligand binding of the pro-
lactin receptor is common to all its isoforms, del1-9-G129R is assumed to
inhibit actions mediated by short and long isoforms.
Cell stimulation and Western blot
Cells were plated in 24-well plates and maintained in DMEM supplemented
with 10% FCS. The next day, cells were washed twice with phosphate-
buffered saline, and then serum starved for 8 hrs prior to stimulation. Cells
were stimulated for 30 min. with different concentrations of prolactin (10,
100, 500, 1000 and 10,000 g/l) in serum-free medium at 37C/5% CO2,
with or without the prolactin receptor antagonist del1-9-G129R-hPRL
(2000 and 10,000 g/l). Next, cells were lysed in Laemmli lysis buffer,
incubated for 5 min. at 95C, and whole cell lysates were separated by 10%
SDS-PAGE. After electrophoresis, proteins were transferred onto immo-
bilon-P PVDF membranes (Millipore, Billerica, MA, USA). Membranes were
incubated overnight at 4C with primary antibodies against tubulin (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), phospho-STAT5 or phospho-
ERK1/2 (both Cell Signalling, Beverly, MA, USA) diluted in TBS with 0.1%
Tween (TBS-T)/1% BSA. All secondary horseradish peroxydase (HRP)-
conjugated antibodies were from DakoCytomation (Glostrup, Denmark).
Blots were imaged using Lumilight Plus ECL substrate (Roche, Basel,
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Switzerland) on a GeneGnome imager (Syngene, Cambridge, UK). Blots
were repeated three times.
Chicken chorioallantoic membrane assay (CAM)
Physiologically developing chicken embryo CAM, at embryo development
day (EDD) 7 and 8 as previously described in detail [30], were exposed 
to human prolactin and/or its antagonist (prolactin:antagonist; 
1:10 g/embryo/day). Prolactin was topically applied (20 l) at a concen-
tration of 1 or 10 g/embryo/day in 0.9% NaCl either alone or mixed 
with its receptor antagonist del1-9-G129R-hPRL (10 g/embryo/day). The
control eggs received (each time 20 l) 0.9% NaCl at the same days. Each
condition was included fourfold. At EDD9, the CAMs were evaluated in vivo
by means of FITC-dextran (20 kD, 25 mg/ml, Sigma-Aldrich) epi-fluores-
cence angiography as described previously [30]. For detecting FITC, light
was filtered for excitation at 470  20 nm and a long-pass emission filter
was used for detection of the fluorescence (  520 nm, Nikon, Japan).
Fluorescence images were acquired with an F-view II 12-bit monochrome
Peltier-cooled digital CCD camera driven with analySIS DOCU software from
Soft Imaging System GmbH (Münster, Germany). Image-processing quan-
tification was performed using ImageJ-based macro as described previ-
ously [31] using the following descriptors: the number of branching
points/mm2 and the number of segments per mm2 (number of vessels
between two branch points). Tortuosity was assessed by visual determina-
tion. Experiments were performed two times.
Proliferation assays 
(MTT and CellTiter-Glo® viability assays)
2H11 endothelial cells seeded at a density of 104/cm2 in 96-well cell cul-
ture plates in DMEM supplemented with 1% FCS were treated with the indi-
cated concentrations of prolactin (10, 100, 1000 and 10,000 g/l) or
serum-free medium as negative control, for 18 hrs at 37C/5% CO2. Cell
survival was determined 2 hrs after addition of MTT reagent as described
before [32]. Proliferation assays with 2H11 were done six times and each
condition was performed in octuplicate.
Additionally, HUVEC (5*103 cells/well) were seeded in gelatin-coated
96-well cell culture plates as described previously [33, 34]. Briefly, 24 hrs
after seeding, serum-free medium alone (control) or serum-free medium
supplemented with a range of prolactin concentrations (10, 100, 1000 and
10,000 g/l) was added and cells were grown for a further 72 hrs at
37C/5% CO2. Cell viability was assessed using the CellTiter-Glo®
Luminescent Cell Viability Assay (Promega, Madison, WI, USA).
Proliferation assays with HUVECs were done two times and each condition
was performed in duplicate or quintuplicate.
Migration assays
2H11 endothelial cells were grown to 90% confluence in DMEM
 supplemented with 3% FCS in T25 cell culture flasks and were subse-
quently incubated with serum-free medium alone (control) or serum-free
medium supplemented with prolactin (1000 g/l), with the antagonist
del1-9-G129R-hPRL, or with prolactin (1000 g/l) in combination with
del1-9-G129R-hPRL (20,000 g/l) for 18 hrs at 37C/5% CO2. Next, cells
were labelled for 1 hr with 10 mol/l CellTracker Green 5-chloromethylflu-
orescein diacetate (CMFDA) (Molecular Probes, Eugene, OR, USA) in
serum-free medium. The dye was fixed by 1 hr incubation in medium with
10% FCS. Subsequently, cells were washed and detached with a cell
scraper, resuspended in serum-free medium until a concentration of
0.510E6 cells/ml and transferred to 8-m pore size HTS FluoroBlok cell
culture inserts (BD Falcon, Franklin Lakes, NJ, USA). Serum-free medium
was added to the bottom compartment and cells were allowed to migrate
from the upper compartment to the bottom compartment. Cell migration
was assessed as described before [32, 35, 36]. Briefly, fluorescence values
representing the number of cells on the bottom side of the insert were read
during 71 cycles (each cycle comprising four readings spanning 2 min.) at
37C. The raw fluorescence data were corrected for background fluores-
cence and fading of the fluorophore. Migration assays with 2H11 were
repeated three times and each condition was included three- to sixfold.
The migration capability of HUVECs was measured using wound
scratch assays [37]. In brief, HUVECs were grown to confluence in gelatin-
coated wells. Scratch wounds were made in the monolayer by removing
cells with a sterile scratch tool (Peira Scientific Instruments, Beerse,
Belgium). Cells were washed with PBS and the medium was replaced by
serum-free medium alone (control) or serum-free medium supplemented
with prolactin (1000 g/l) for 8 hrs at 37C/5% CO2. Plates were scanned
using an Acumen eX3 laser scanner cytometer (TTP LabTech Ltd, Royston,
UK) to acquire images for computational analysis of scratch sizes using
UGR Scratch Assay 6.2 software (DCI Labs, Peira Scientific Instruments,
Beerse, Belgium). Narrowing of the sizes of the scratches is referred to as
‘wound closure’. In this assay, phase-contrast micrographs of six marked
points along the wounded area for each condition were compared at t 	 0
hr and t 	 18 hrs. More specifically, we rated at each time point the wound
recovery in control condition, compared it in cells stimulated with pro-
lactin, and assessed the recovery induced by prolactin as percentage of the
control condition at t 	 18 hrs. Migration assays with HUVECs were
repeated three times and each condition was included at least fivefold.
Endothelial tube formation assay
Endothelial tube formation assays were essentially performed as described
before [25]. Briefly, cells (5*104/well) in serum-free medium alone (con-
trol) or serum-free medium with prolactin (10, 100, 1000 and 10,000 g/l)
and/or del1-9-G129R-hPRL (20,000 g/l) were resuspended in 0.3 ml of
the indicated medium, and plated on 24-well plates pre-coated with growth
factor-reduced Matrigel (0.15 ml). After 18 hrs at 37C/5% CO2, each well
was examined for endothelial cells alignment using a phase contrast tube
microscope (Carl Zeiss MicroImaging, Inc. Thornwood, NY, USA). As
described in a paper by Aranda and Owen [38], a tube is a capillary-like
structure, defined by the remodelling of endothelial cells in Matrigel, result-
ing from the general process of cell elongation and reorganization. We
adapted this definition with more stringent criteria and we therefore quan-
tified in each field the number of branching polygons (enclosed structures
in Matrigel with internal holes) formed by connected cells. This method is
well established and validated [39–42]. For quantification of endothelial
tube formation, the number of tubes was counted in each well (divided in
five fields) in a blinded fashion. The tube formation observed after incuba-
tion with serum-free medium only was set at 100% and used as reference.
Tube formation assays were repeated three times.
Immunohistochemistry and spectral imaging
Breast carcinoma tissue [invasive ductal carcinoma, T2N1, oestrogen
receptor negative, progesteron receptor negative, Human Epidermal
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growth factor Receptor 2 (HER2/neu): negative] was retrospectively
obtained from the diagnostic archive of the department of pathology
(Academic Medical Center Amsterdam, The Netherlands), in accordance
with guidelines set out by the ‘Code for Proper Secondary Use of Human
Tissue’ of the Dutch Federation of Biomedical Scientific Societies (Federa).
Routinely formalin-fixed and paraffin-embedded tissue blocks were cut 
(4 m sections), deparaffinized in xylene and rehydrated in graded series
of alcohol washings. Endogenous peroxidase activity was blocked with
methanol plus 0.3% peroxide for 20 min. at room temperature [43]. Tissue
pretreatment with Tris-EDTA pH 9.0 (Thermo Fisher/Labvision, Fremont,
CA, USA) was performed in the PTModule (Thermo Fisher
Scientific/Labvision) for 20 min. at 98C followed by a cool-down to 75C.
Ultra V Block (Thermo Fisher Scientific/Labvision) was applied for 10 min.
at room temperature. After blocking, the primary monoclonal antibody rec-
ognizing the prolactin receptor (clone 1A2B1, mouse IgG2b;
Zymed/Invitrogen, Carlsbad, CA, USA) was diluted (1:500 v/v) in antibody
buffer (Scytek Labs, Logan, UT, USA) and incubated overnight at 4C. This
antibody reacts with the long form of the human prolactin receptor and
may identify the human prolactin receptor intermediate and 
S1 isoforms
(Zymed/Invitrogen datasheet). Isotype-matched negative control antibody
(mouse IgG2b; Dako, Glostrup, Denmark) was applied in a concentration
that matched with the prolactin receptor antibody. Tris-buffered saline was
used for washing (32 min.). A three-step HRP polymer immunohisto-
chemistry (IHC) detection technique was applied: post-antibody blocking,
1:1 diluted in Scytek antibody diluent (30 min., room temperature) followed
by anti-mouse/rabbit/rat Powervision polymer/HRP (both ImmunoVision,
ImmunoLogic, Duiven, The Netherlands), 1:1 diluted in Scytek antibody
diluent (30 min., room temperature); HRP activity was visualized with
diaminobenzidine (Bright DAB, ImmunoLogic) after 8 min. Sections were
counterstained with haematoxylin (Klinipath, Duiven, The Netherlands) and
mounted with VectaMount (Vector Labs, Burlingame, CA, USA). To confirm
prolactin receptor expression in endothelial cells, a sequential double stain-
ing was performed with the prolactin receptor antibody [44] and an anti-
body directed against CD34 (clone QBend10, mouse monoclonal, Thermo
Fisher Scientific/Labvision). Prolactin receptor antibody binding was
detected with a two-step HRP polymer technique as described above. HRP
activity was visualized in grey with Vector ImmPACT SG (Vector Labs,
Burlingame, CA, USA). Next, CD34 antibody binding was detected with an
anti-mouse AP-conjugated polymer (ImmunoLogic) and AP activity was
visualized in red using Vector Red (Vector Labs). Potential cross-reactivity
between both stainings was tested in control slides leaving out the CD34
antibody. Sections were counterstained with 0.1% methylgreen and
mounted with VectaMount. Slides were analysed by light microscopy
(Olympus BX51 microscope, Olympus UPlanFl 20 objective, Olympus
DP70 digital camera; Olympus, Zoeterwoude, The Netherlands). In addition,
double-stained IHC slides were analysed by the Nuance multispectral imag-
ing system and software (Caliper Life Sciences/Cambridge Research and
Instrumentation, Inc., Woburn, MA, USA) [45]. Datasets were acquired
from 420 to 720 nm at 20 nm intervals. Using the Nuance software version
3.0 and a spectral library of single Vector ImmPACT SG, single Vector Red
and methylgreen multiple staining tissue specimens were unmixed into the
individual components. The Nuance software was also used for making an
exclusive image of prolactin receptor and CD34  co-localization. All slides
were analysed by an independent pathologist.
Statistical analysis
Statistical analyses were conducted using GraphPad Prism version 5.0
software (San Diego, CA, USA). Data were plotted with GraphPad as well
and expressed as means  standard error of the mean. Comparisons
between two conditions were analysed using Student’s t-tests (tube 
formation and proliferation) when the results were normally distributed,
and Mann–Whitney test otherwise. A P value  0.05 was considered to
confer significance.
Results
Activation and blockade of the prolactin receptor
Upon activation of the prolactin receptor, the JAK-STAT signalling
pathway is activated, with STAT5 as the primary mediator of pro-
lactin action [2]. Additionally, ERK1/2 phosphorylation is also a
major downstream target of prolactin receptor signalling [2].
Hence, we investigated the phosphorylation of STAT5 and ERK1/2
after exposure of 2H11 cells to a dose range of prolactin. As
shown in Figure 1, prolactin induced a concentration-dependent
phosphorylation of ERK1/2, starting at 10 g/l and culminating at
1000 g/l (lane 5–8). Phosphorylation of ERK1/2 was decreased
when using 10,000 g/l prolactin (lane 9). Prolactin also induced
the phosphorylation of STAT5, starting at 10 g/l and peaking at
10,000 g/l (lane 5–9). Moreover, ERK1/2 and STAT5 phosphory-
lation induced by prolactin was completely abolished by addition
of 20-fold molar excess of the prolactin receptor antagonist del1-
9-G129R-hPRL (lane 1 and 2 compared to 6 and 7). The antago-
nist alone, even at extremely high concentrations (10,000 g/l),
failed to notably induce signalling (lane 3 and 4) (Fig. 1). Overall,
these data demonstrate that prolactin has a direct effect on
endothelial cells, which is mediated by the prolactin receptor.
Prolactin induces angiogenesis in the CAM
The angiogenic activity of prolactin was investigated in vivo using
the early chicken embryo CAM assay. In control-treated embryos
(0.9% NaCl), the capillary plexus was well developed and a homo-
geneous vascularization was observed (Fig. 2A). Topical adminis-
tration of prolactin induced a clear change in the morphology of
the vasculature (Fig. 2B). Digital analysis of the images did not
reveal a change in the number of branching points:
1987(58.87)/mm2 in the control condition versus
2124(190.1)/mm2, P 	 0.39, after addition of 1 g prolactin
and 2088(85.71)/mm2, P 	 0.34, after addition of 10 g
 prolactin (Fig. 2D). By contrast, 10 g prolactin induced a clear
increase in vessel density compared to control
[3683(142.4)/mm2 versus 3337(36.5)/mm2, respectively, 
P 	 0.0065; Fig. 2E], whilst addition of 1 g prolactin had no
effect on vessel density [3549(340.2)/mm2, P 	 0.42].
Combination of 1 g prolactin with 10 g of the prolactin recep-
tor antagonist did not significantly affect the number of branching
points [1885(252.3)/mm2, P 	 0.37; Fig. 2D] in comparison to
the control condition. Additionally, prolactin plus antagonist did
J. Cell. Mol. Med. Vol 16, No 9, 2012
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Fig. 1 Prolactin exerts a direct effect on endothelial cells. 2H11 endothelial cells, serum starved for 8 hrs, were stimulated for 30 min. with prolactin (10,
100, 500 or 1000 g/l; lane 5–9) or with prolactin (100 or 500 g/l) in combination with the prolactin receptor antagonist del1-9-G129R-hPRL (‘Anta’;
2000 or 10,000 g/l; lane 1 and 2) or with del1-9-G129R-hPRL alone (2000 or 10,000 g/l; lane 3 and 4). Cell lysates were analysed using Western blot
for phosphorylated STAT5 (‘Phospho-STAT5’; top panel), phosphorylated ERK1/2 (‘Phospho-ERK1/2’; middle panel) and tubulin as loading control (bot-
tom panel). A representative picture of an experiment is shown, which was performed three times with similar results.
Fig. 2 Effect of prolactin on in vivo angiogenesis
in the CAM. Images show the CAM (EDD9) 
with or without treatment with prolactin (PRL)
and prolactin with its receptor antagonist
(PRLAnta). The vasculature is visualized by
FITC-dextran fluorescence angiography (25
mg/kg, 20 kD, ex	 470 nm). (A) Untreated CAM
with small vessels and the capillary network. (B)
Angiography of a CAM treated with prolactin 
(1 g/embryo/day). (C) Angiography after treat-
ment with prolactin (1 g/embryo/day) mixed with
its receptor antagonist (10 g/embryo/day).
Scale bar in (A) is valid for all three images.
Arrows indicate the induced pillar formation and
intussusceptive angiogenesis in the larger blood
vessels. (D, E) Quantification of digital analysis
of the angiography images. (D) Branching
points/mm2 for CAM, stimulated with 0.9%
NaCl alone (control, white bar) or 0.9% NaCl
supplemented with the indicated amounts of
prolactin (PRL, black bars) or prolactin with
antagonist (PRL  Anta, grey bar). (E) Number
of segments/mm2 as a marker of vessel density
for CAM, stimulated with 0.9% NaCl alone (con-
trol, white bar) or 0.9% NaCl supplemented with
the indicated amounts of prolactin (PRL, black
bars) or prolactin with antagonist (PRL  Anta,
grey bar). Mean values ( standard error of the
mean) are shown for two different experiments,
in which each condition was included four times
(thus eight individual eggs). **P  0.01.
2040 © 2012 The Authors
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not influence the number of segments [3314(398.0)/mm2, P 	
0.85; Fig. 2E]. Moreover, prolactin enhanced the tortuosity of the
vessels (Fig. 2B). The exposure to prolactin induced pillar forma-
tion and intussusceptive angiogenesis in the larger blood vessels
(arrows in Fig. 2B), phenomena that are known to occur after
exposure to the angiogenic growth factor VEGF [46, 47]. These
effects of prolactin were markedly diminished by addition of the
prolactin receptor antagonist del1-9-G129R-hPRL (Fig. 2C).
Effect of prolactin on endothelial cell survival
To investigate whether prolactin has a direct effect on the viability
of endothelial cells, cultured cells of the 2H11 cell line were
exposed to a dose range of prolactin (from 10 to 10,000 g/l) for
18 hrs and cell proliferation was assessed using the MTT assay.
From 100 g/l onwards, prolactin induced a subtle, but signifi-
cant, increase in cell proliferation (105.5  2%, P 	 0.048; 115.4
 3%, P  0.0001 and 116.9  4%, P 	 0.0005 for 100, 1000
and 10,000 g/l prolactin, respectively; Fig. 3A). Similar results
were obtained with human endothelial cells of primary origin
(HUVEC; Fig. 3B). We observed that 100, 1000 and 10,000 g/l
prolactin induced an even more discrete proliferation of HUVECs
(109.2  2%, P 	 0.003; 105.0  2%, P 	 0.098 and 105.3 
2%, P 	 0.038, respectively).
Prolactin stimulates endothelial cell migration
Another hallmark of angiogenesis is the capacity of endothelial
cells to migrate. To test for migratory activity, dose ranges of pro-
lactin were tested in a migration assay using 2H11 endothelial
cells. While virtually no migration was observed in control condi-
tions, exposure to 1000 g/l of prolactin significantly enhanced
migration (P  0.0001; Fig. 4A). Again, the antagonist del1-9-
G129R-hPRL almost completely reverted the effects of prolactin
on cell migration (P  0.0001; Fig. 4A), demonstrating the
involvement of prolactin receptor in prolactin-induced migration.
To confirm these results with human endothelial cells of pri-
mary origin (HUVEC), a wound scratch assay was performed
using the same concentration of prolactin. Wound closure was
monitored for 8 hrs. Representative pictures of the experiment
showed that prolactin stimulated wound closure as compared to
the control (Fig. 4B–E). Quantification of the wound closure con-
firmed that prolactin significantly enhanced cell migration by
117.0  4%, (P 	 0.010) (Fig. 4F).
Fig. 3 Prolactin slightly stimulates proliferation of endothelial cell cultures. (A) MTT assay on a cell culture of the 2H11 endothelial cell line in serum-free
medium (control, white bar) or in serum-free medium supplemented with the indicated concentrations of prolactin (PRL, black bars). The mean ( stan-
dard error of the mean) of six different experiments performed in octuplicate is shown. (B) CellTiterGlo assay using primary human endothelial cells
HUVECs in serum-free medium (control, white bar) or serum-free medium supplemented with the indicated concentrations of prolactin (PRL, black bars).
The mean ( standard error of the mean) of two different experiments is shown, in which each condition was included either two or five times. Results
shown in (A) and (B) are expressed as relative induction of proliferation (% of control). ***P  0.001, **P  0.01, *P  0.05.
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Prolactin stimulates tube formation
We further investigated the effect of prolactin on an in vitro assay of
tube formation as defined by others [38–41, 48]. 2H11 cells were
cultured on a semi-natural, growth factor reduced, matrix (Matrigel)
for 18 hrs. Figure 5A–C are representative pictures of the formation
of tube-like structures consisting of anastomosing vasculature-like
structures, in response to serum-free medium (A), prolactin 1000
g/l (B) and prolactin 1000 g/l in combination with antagonist
20,000 g/l (C). Addition of prolactin stimulated tube formation in
a dose-dependent manner (Fig. 5D), with a trend towards an
increase for concentrations as low as 10 and 100 g/l, and a signif-
Fig. 4 Prolactin stimulates endothelial cell migration.
(A) Trans-well migration towards serum-free medium
of 2H11 cells. Cells were stimulated for 18 hrs either
with 1000 g/l prolactin (PRL), serum-free medium
(SF), the prolactin receptor antagonist del1-9-G129R-
hPRL (Anta) alone (20,000 g/l) or prolactin 1000 g/l
in combination with del1-9-G129R-hPRL 20,000 g/l
(PRLAnta). Fluorescence was measured every 2 min.
at the bottom side of the well. The level of fluorescence
is shown and is representative for the number of
migrated cells in time [relative fluorescence units
(RFU)]. A representative example of an experiment per-
formed three times is shown, in which each condition
was included three- to sixfold. (B–E) Migration of
HUVECs as assessed in the wound scratch assay. After
the wound scratch was performed, serum-free
medium (control) or serum-free medium supple-
mented with prolactin (PRL, 1000 g/l) was added and
wound closure was monitored for 8 hrs. (B) and (D)
are representative pictures of the wound at t 	 0 hr. (C)
Representative picture of wound closure after 8-hr
incubation in the control condition. (E) Representative
picture of wound closure after 8-hr incubation with
prolactin (1000 g/l) over this period. Blue colour rep-
resents the digital calculated wound area, used for the
analyses. (F) Quantification of wound closure with pro-
lactin (PRL, black bar) expressed as percentage of the
control (white bar). Mean values ( standard error of
the mean) for three different experiments are shown.
Each condition was included at least fivefold. ***P 
0.001, *P  0.05.
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icant induction from 1000 g/l (216.6  42%, P 	 0.036)
onwards, with a maximal induction of over threefold at 10,000 g/l
(327.3  78%, P 	 0.017), as compared to serum-free medium
alone. As shown in Figure 5C and E, administration of the prolactin
receptor antagonist del1-9-G129R-hPRL at a concentration of
20,000 g/l dramatically reduced tube formation induced by 1000
g/l prolactin to the level of the control condition (P 	 0.017).
Prolactin receptor is expressed on endothelial
cells in breast cancer tissue – spectral imaging
Given the recognized stimulating effect of prolactin on the devel-
opment of breast cancer [7, 10–12, 15], we aimed to investigate
the potential clinical relevance of our in vivo and in vitro findings.
To this end, we explored whether endothelial cells in breast
Fig. 5 Prolactin promotes endothelial tube formation. The 2H11 endothelial cells (5*104/well) were resuspended in (A) serum-free medium (control), (B) pro-
lactin (PRL, 1000 g/l) and (C) prolactin (1000 g/l) in combination with antagonist del1-9-G129R-hPRL (PRLAnta 20,000 g/l) and tube formation was
assessed after 18 hrs. The representative pictures of an experiment performed three times are shown. (D) Quantification of tube formation in the control con-
dition (white bar) or 10–10,000 g/l prolactin (PRL, black bars). (E) Quantification of tube formation in the control condition (white bar) or del1-9-G129R-
hPRL alone (striped bar) or 1000 g/l prolactin (PRL, black bar) or prolactin in combination with del1-9-G129R-hPRL (grey bar). (D–E) are shown as mean
values ( standard error of the mean) for three different experiments. *P  0.05 compared to the control, ^P  0.05 in comparison to prolactin 1000 g/l.
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 carcinoma tissue express the prolactin receptor. Hence, we
stained breast carcinoma tissue immunohistochemically, using a
monoclonal antibody directed against the human prolactin
 receptor. The antibody was tested on placental tissue and stained
positively for decidual cells as previously described [42].
Galsgaard et al. have elegantly evaluated the specificity of the
commercially available anti-human PRLR antibodies (B6.2, U5,
PRLRi pAb, 1A2B1, 250448 and H-300). The monoclonal antibody
1A2B1 was found to be the most specific for detection of PRLR in
immunohistochemistry applications, therefore we choose to use it
Fig. 6 Immunohistochemical staining of the
prolactin receptor and CD34 in mammary
carcinoma. (A) Staining of the prolactin
receptor (turquoise) and CD34 (endothelial
cells, purple), counterstaining with haema-
toxylin (blue). The pictures were digitally
processed to unmix the different colours.
(B) Fluorescence-like image of both pro-
lactin receptor (green) and CD34 (red) in
pseudo-colours. (C) Areas where prolactin
receptor and CD34 co-localize, and
endothelial expression of prolactin receptor.
(D) and (E), respectively, show pseudo-flu-
orescent staining for the prolactin receptor
(green), endothelial cells (red) and nuclei
(blue). Scale bar 	 0.075 m in (A–E).
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in our study [44]. The placenta tissue was fully negative with the
isotype control [42]. The sequential double staining control did
not show any signs of cross-reactivity between both staining
sequences (data not shown). As such, this proves that the Vector
ImmPACT SG grey reaction product shields the immunoreagents
of the first sequence very effectively as is also reported for
diaminobenzin reaction product [49].
Figure 6A demonstrates the double staining for prolactin
receptor (turquoise) and CD34 (purple) in breast carcinoma tis-
sue. To investigate the expression of the prolactin receptor on
CD34- positive endothelial cells, spectral imaging was used to
unmix both stains. After spectral unmixing, pseudo-coloured
 fluorescence-like images, as well as exclusive images of co-
 localization, were obtained. While Figure 6B shows double stain-
ing, this technique is able to show the co-localization of both
 signals (yellow), indicating endothelial expression of prolactin
receptor (Fig. 6C). Figure 6D and E show the single signals for
prolactin receptor and endothelial cells, respectively, counter-
stained with haematoxylin.
Discussion
Physiologically, angiogenesis plays an important role during
embryogenesis, and after birth, it contributes to organ growth.
During adulthood, most blood vessels remain quiescent, and
physiological angiogenesis occurs only in the cycling ovary, in the
placenta during pregnancy and during wound healing [50].
Nonetheless, in many disorders, such as heart failure [51],
ischaemic heart disease [52], pre-eclampsia [53], malignancy
[54], ocular [55] and inflammatory disorders [56], angiogenesis
escapes its self-limiting control thereby leading to the progression
of these pathologies.
In this study, we show for the first time that prolactin is able
to directly signal to endothelial cells. We observed phosphoryla-
tion of STAT5 and ERK1/2, which both have been shown to be
involved in the induction of angiogenic events, such as prolifera-
tion, migration and tube formation of endothelial cells [57–60].
Additionally, ERK1/2 and Stat 5 activation by other agonists (such
as angiopoietin-2, interleukin beta-1, 15(S)-hydroxyeicosate-
traenoic acid, etc.) in other cell types (myoblasts, chondrocytes,
neuronal cells, etc.) lead to differential regulation of a plethora of
genes, related with angiogenesis events [61–64]. For instance, in
chondrocytes, IL-1beta induced ERK1/2 phosphorylation but dis-
crete gene expression and ERK1/2 activation by mechanical
forces induced VEGF expression [62]. Additionally, observations
in human retinal microvascular endothelial cells suggest that
15(S)-HETE-induced angiogenesis requires Jak2-STAT-5B-
dependent expression of IL-8 [63]. Interestingly, we repeatedly
observed slightly less ERK1/2 phosphorylation in response to
10,000 g/l prolactin than to 1000 g/l, whilst such an effect was
not detectable for STAT5 phosphorylation. Bell-shaped curves in
prolactin receptor mediated dose-response assays have been
reported in the past and were referred to as self-antagonism of
prolactin at high concentration [65, 66].
We additionally demonstrated that functional consequences of
prolactin signalling on endothelial cells relate to angiogenesis. More
specifically, we showed that prolactin induces an increase in vessel
density and tortuosity in the CAM assay, and rearrangement of
endothelial cells into tube structures on Matrigel. We demonstrated
that prolactin induces a robust migration of endothelial cells.
Importantly, we found that prolactin-induced signalling and angio-
genesis were markedly diminished by the specific prolactin receptor
antagonist del1-9-G129R-hPRL, thereby suggesting that the
observed effects in response to prolactin are prolactin-receptor spe-
cific. Finally, we observed that the prolactin receptor is expressed in
endothelial cells of vessels in breast carcinoma tissue. Overall, our
data provide new insights on how prolactin may contribute to the
progression of angiogenesis-related pathologies, such as, among
other, breast cancer progression, where the role of prolactin has
been particularly well studied. Indeed, it is now known that prolactin
is synthesized by mammary epithelial cells [67, 68]. Breast cancer
mortality is predominantly due to metastasis, which is partly
dependent on cell survival and motility. Previous studies focusing
on epithelial breast cancer cells showed that prolactin triggers
cytoskeletal reorganization and subsequent cell motility and inva-
sion [69–71]. Moreover, exogenous prolactin is mitogenic and anti-
apoptotic in breast cancer cells, and overexpression of autocrine
prolactin cDNA in breast cancer cell lines has been shown to stim-
ulate their growth and to protect against chemotherapy-induced
apoptosis. Autocrine prolactin acts as an inducible survival factor in
clonogenic subpopulations of breast cancer cells [72]. In addition,
in vitro treatment of human macrophages, the HC11 mouse mam-
mary epithelial cell line and NB2 rat lymphoma cells with prolactin
resulted in enhanced release of VEGF, providing an additional mech-
anism by which prolactin may (indirectly) contribute to tumour
growth and metastasis [20, 21]. Our results shed light on a novel
potential aspect by which prolactin might influence tumour progres-
sion. In addition to targeting epithelial breast cancer cells and
inflammatory cells, prolactin exerts a pleiotropic role by affecting
endothelial cells and influencing angiogenesis, thereby creating a
favourable microenvironment for tumour growth and metastasis. Of
note, angiogenesis does not initiate malignancy, but stimulates
tumour progression and metastasis [50].
At the cellular level, angiogenesis comprises two different
mechanisms: endothelial sprouting and intussusceptive microvas-
cular growth [46]. The sprouting process is based on endothelial
cell migration, proliferation and tube formation [73]. Several lines
of evidence in our study strongly suggest that the proangiogenic
effects of prolactin are rather due to the induction of endothelial
cell motility than proliferation. Indeed, its effect on cell prolifera-
tion was subtle. In addition, the duration of our migration assays
(i.e. 142 min. for Boyden chamber assay and 8 hrs for the wound
scratch assay) suggest that the effects of prolactin do not likely
rely on cell proliferation. These results are in line with another
study demonstrating that high prolactin concentrations alter the
actin cytoskeleton of endothelial cells in vitro [22]. It is notewor-
thy that we detected ERK1/2 and Stat5 phosphorylation already
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with 100 g/l prolactin. However, it must be kept in mind that a
robust and sustained phosphorylation of protein kinases is
required to lead to relevant functional consequences. The phos-
phorylation of ERK1/2 and Stat 5 were analysed at a short time
frame (i.e. 30 min.), to decipher whether prolactin could directly
induce their activation. Therefore, it is not possible from these par-
ticular experiments to draw conclusions on whether 100 g/l of
prolactin is able to induce a signal strong enough to have func-
tional consequences such as cell proliferation, migration or
rearrangement. In keeping with this concept, as shown in Figures
3 and 5, 100 g/l prolactin did not induce significantly tube 
formation, and led to a very discrete induction of proliferation
(105.5  2%, P 	 0.048). Therefore, whereas the sensitivity of
the antibodies used with Western blot allows detecting a signal at
this relatively low concentration of prolactin, it is very likely that
the induced signalling is not robust enough to induce functional
consequences with potential relevance in pathophysiology. 
We therefore choose to continue working with relatively high 
concentrations of prolactin in the migration, wound closure and
CAM assays.
Growth and remodelling in the angiogenic process, on the
other hand, result from intussusceptive angiogenesis alone, which
involves transluminal tissue pillar formation and subsequent vas-
cular splitting [46]. Struman and others have already shown that
prolactin stimulated new capillary and blood vessel formation in
the late-stage CAM assay (day 10–14), whilst they did not observe
such an effect of prolactin in the early-stage CAM assay (day 6–8)
[19]. These data are in line with ours, since we did not observe an
effect of prolactin branching points in the early-stage CAM assay
(day 7–9). However, we did find that prolactin increases the num-
ber of segments and the tortuosity of vessels in the CAM assay,
and induced pillar formation, which is indeed indicative of intus-
susceptive angiogenesis [46]. Interestingly, the latter is an activity
that is also seen in the action spectrum of VEGF [74]. Overall, our
data suggest that prolactin affects both sprouting- and intussus-
ceptive angiogenesis. Remarkably, while we did see a stimulatory
effect of prolactin on endothelial cell migration, we did not find an
effect on branching points in the CAM assay. We favour the view
that the angiogenic activity of prolactin is subtle and in the CAM
may be masked by the angiogenic cytokine storm of the develop-
mental process.
Several issues should be kept in mind when interpreting the
data. First, only a single sample of mamma carcinoma tissue was
stained. All together the results of our study support a role for pro-
lactin in angiogenesis, however, future larger studies should
assess whether the levels of prolactin receptor expression on
endothelial cells in different stages of breast carcinoma tissues.
Second, as reviewed by Clapp and co-workers, the roles of pro-
lactin and its receptor on endothelial biology may be tissue-specific
[75], which may be explained by a tissue-dependent difference in
prolactin receptor heterogeneity and autocrine prolactin expression
in vasculature per se. This hypothesis might explain the discrepan-
cies between our and others studies. In line with our data (show-
ing little if any effect of prolactin on endothelial cell proliferation),
incubation of 805 g/l prolactin on bovine brain capillary endothe-
lial cells up to 3 days induced a modest but not significant effect on
proliferation [19, 76], and the same results were observed for 48
hrs incubation of rat retinal capillary endothelial cells with 2.3 to
2300 g/l prolactin [77]. Castilla et al. on the other hand observed
a significant effect of proliferation of bovine umbilical vein endothe-
lial cells in response to follicular fluid containing almost 100 g/l
prolactin [78]. Additionally, Malaguarnera et al. showed a dual
effect of prolactin on cell proliferation: at low concentration (10 and
25 g/l), prolactin induced considerable proliferation of human
dermal microvessel endothelial cells (approximately 160% and
170%, respectively), while no proliferation was observed in
response to 100 g/l prolactin [79]. Moreover, in contrast with our
data, using 10 and 25 g/l of prolactin, these authors observed
only a modest effect on tube formation on Matrigel (approximately
113% and 120%, respectively) [79]. In the present study, we used
two different endothelial cell types in our assays. We made use of
both the 2H11 endothelial cell line, which are an accepted model of
endothelial cells for angiogenesis assays as they express several
well-recognized normal tissue endothelial cell markers [25, 26] and
HUVECs. The current proliferation and migration data were compa-
rable for HUVECs and 2H11. Third, the concentrations of prolactin
we used might seem unusually high. However, one should keep in
mind that auto/paracrine prolactin production is increased in breast
cancer [80], as epithelial breast cancer cells may be a source of an
elevated local prolactin concentration [11]. We therefore chose to
use these relatively high doses of prolactin in our experiments.
Fourth, other studies showed that modified forms of prolactin
(such as phosphorylated prolactin or the 16-kD N-terminal 
fragment of prolactin) have anti-angiogenic properties [81, 82].
Erdmann and co-workers elegantly showed that the bovine 
corpus luteum is able to produce prolactin and to process it into
antiangiogenic fragments by cathepsin D activity and that prolactin
cleavage might mediate angioregression during luteolysis [16].
Nonetheless, it was hypothesized that 16-kD prolactin exerts its
effects via a different receptor, possibly belonging to the 
superfamily of the proliferin receptor [83]. Thus, it might be 
difficult to compare the results obtained with 16-kD prolactin and
the full-length hormone. Phosphorylated prolactin (derived from
the pituitary) [82] has been shown to have anti-angiogenic proper-
ties. However, autocrine prolactin, secreted by mammary epithelial
cells, is unmodified, based on the ability of this autocrine prolactin
to promote NB2 cell proliferation [68], thereby explaining the 
discrepancies in the effects on angiogenesis on the different forms
of prolactin.
In conclusion, we propose that prolactin plays a role in the
induction of angiogenesis, as a result of direct interaction with
endothelial cells. This may provide a potential additional link with
the progression of breast cancer. Endothelial cells are considered
ideal therapeutic targets that would not become resistant to anti-
angiogenic therapy. Indeed, the first anti-angiogenic agents have
been approved for the treatment of tumour growth and metastasis
by targeting endothelial, mural, stromal, haematopoietic and neo-
plastic cells, which release an array of chemokines and cytokines
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